In this episode of The Crux of Cardio, Jordan Burgin sits down with Ken Nelson, one of the most experienced commercial leaders in cardiac digital health.

Ken helped scale commercial teams at iRhythm, BioTelemetry/CardioNet, and Bardy Diagnostics, three of the defining names in ambulatory cardiac monitoring. He shares the inside story behind the 2020–2021 cardiac monitoring M&A wave, including Philips’ acquisition of BioTelemetry, Hillrom’s acquisition of BardyDx, and Boston Scientific’s acquisition of Preventice.

The conversation also covers the Medicare reimbursement shock that nearly derailed the Bardy transaction, the court decision that forced Hillrom to complete the deal, and the personal loss that now shapes Ken’s work as an investor, board member, and mentor across cardiac and EP startups.